Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-21-000350
Filing Date
2021-03-18
Accepted
2021-03-18 21:59:48
Documents
1
Period of Report
2021-03-16

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 8816
  Complete submission text file 0000947871-21-000350.txt   11119
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Issuer) CIK: 0001534248 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel GP Ltd. (Reporting) CIK: 0001569590 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38807 | Film No.: 21756385

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Reporting) CIK: 0001569821 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38807 | Film No.: 21756384